Perrigo (PRGO) Competitors $25.74 +0.12 (+0.47%) Closing price 04/30/2025 03:59 PM EasternExtended Trading$25.10 -0.64 (-2.49%) As of 07:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PRGO vs. CORT, JAZZ, SUPN, PCRX, OMER, NKTR, ASMB, CPIX, LLY, and JNJShould you be buying Perrigo stock or one of its competitors? The main competitors of Perrigo include Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Omeros (OMER), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceuticals" industry. Perrigo vs. Corcept Therapeutics Jazz Pharmaceuticals Supernus Pharmaceuticals Pacira BioSciences Omeros Nektar Therapeutics Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson Perrigo (NYSE:PRGO) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends, community ranking and analyst recommendations. Is PRGO or CORT more profitable? Corcept Therapeutics has a net margin of 22.35% compared to Perrigo's net margin of -3.64%. Corcept Therapeutics' return on equity of 24.54% beat Perrigo's return on equity.Company Net Margins Return on Equity Return on Assets Perrigo-3.64% 7.38% 3.18% Corcept Therapeutics 22.35%24.54%20.24% Does the media favor PRGO or CORT? In the previous week, Corcept Therapeutics had 1 more articles in the media than Perrigo. MarketBeat recorded 13 mentions for Corcept Therapeutics and 12 mentions for Perrigo. Corcept Therapeutics' average media sentiment score of 1.43 beat Perrigo's score of 0.99 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, PRGO or CORT? Corcept Therapeutics has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPerrigo$4.37B0.80-$12.70M-$1.25-20.59Corcept Therapeutics$675.04M11.23$106.14M$1.2457.97 Does the MarketBeat Community prefer PRGO or CORT? Perrigo received 225 more outperform votes than Corcept Therapeutics when rated by MarketBeat users. However, 71.37% of users gave Corcept Therapeutics an outperform vote while only 66.35% of users gave Perrigo an outperform vote. CompanyUnderperformOutperformPerrigoOutperform Votes77166.35% Underperform Votes39133.65% Corcept TherapeuticsOutperform Votes54671.37% Underperform Votes21928.63% Do analysts rate PRGO or CORT? Perrigo presently has a consensus target price of $33.00, indicating a potential upside of 28.21%. Corcept Therapeutics has a consensus target price of $143.25, indicating a potential upside of 99.29%. Given Corcept Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Corcept Therapeutics is more favorable than Perrigo.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Perrigo 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Corcept Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, PRGO or CORT? Perrigo has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Do institutionals & insiders have more ownership in PRGO or CORT? 95.9% of Perrigo shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 0.7% of Perrigo shares are owned by company insiders. Comparatively, 20.5% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryCorcept Therapeutics beats Perrigo on 14 of the 18 factors compared between the two stocks. Get Perrigo News Delivered to You Automatically Sign up to receive the latest news and ratings for PRGO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRGO vs. The Competition Export to ExcelMetricPerrigoPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3.51B$6.89B$5.56B$18.97BDividend Yield4.60%3.05%5.11%4.02%P/E Ratio-22.007.4422.4832.71Price / Sales0.80242.70395.9327.84Price / Cash4.7965.8538.1817.53Price / Book0.736.516.774.47Net Income-$12.70M$143.21M$3.22B$1.02B7 Day Performance3.50%1.98%1.47%0.50%1 Month Performance-6.99%6.89%3.99%-2.83%1 Year Performance-21.76%-2.52%16.15%4.36% Perrigo Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRGOPerrigo4.8648 of 5 stars$25.74+0.5%$33.00+28.2%-21.2%$3.51B$4.37B-22.008,900Upcoming EarningsDividend AnnouncementShort Interest ↑CORTCorcept Therapeutics4.8329 of 5 stars$70.95-1.1%$143.25+101.9%+208.2%$7.49B$675.04M56.31300Upcoming EarningsShort Interest ↓Positive NewsJAZZJazz Pharmaceuticals4.7968 of 5 stars$112.89+1.9%$187.71+66.3%+5.6%$6.86B$4.07B15.903,200Upcoming EarningsAnalyst RevisionNews CoveragePositive NewsSUPNSupernus Pharmaceuticals3.143 of 5 stars$32.25+0.1%$36.00+11.6%+7.9%$1.80B$661.82M30.14580Upcoming EarningsPCRXPacira BioSciences1.9299 of 5 stars$27.14+5.5%$26.67-1.7%+2.5%$1.26B$700.97M-13.37720Upcoming EarningsPositive NewsGap UpOMEROmeros3.7355 of 5 stars$7.27-0.5%$22.50+209.5%+133.3%$422.13MN/A-3.15210NKTRNektar Therapeutics4.0876 of 5 stars$0.76-2.5%$4.50+495.4%-45.5%$140.66M$98.43M-0.90220Upcoming EarningsPositive NewsASMBAssembly Biosciences3.661 of 5 stars$10.82+1.1%$33.00+205.0%-8.7%$82.64M$28.52M-1.61100Upcoming EarningsNews CoverageCPIXCumberland Pharmaceuticals0.8711 of 5 stars$4.77-4.0%N/A+201.9%$66.63M$37.87M-6.1980Upcoming EarningsShort Interest ↓News CoveragePositive NewsLLYEli Lilly and Company4.9193 of 5 stars$877.25-0.8%$1,000.32+14.0%+15.1%$831.78B$45.04B74.9139,000Analyst DowngradeJNJJohnson & Johnson4.3103 of 5 stars$155.36+0.5%$171.82+10.6%+8.1%$373.81B$89.33B23.36152,700 Related Companies and Tools Related Companies Corcept Therapeutics Competitors Jazz Pharmaceuticals Competitors Supernus Pharmaceuticals Competitors Pacira BioSciences Competitors Omeros Competitors Nektar Therapeutics Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Eli Lilly and Company Competitors Johnson & Johnson Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PRGO) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perrigo Company plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Perrigo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRGO Stock Free PRGO Stock Alerts